Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Leukemia Research
|
June 18, 2021
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy
Anthony M Hunter, Najla Al Ali, Anne Mai, et al.
Blood Advances
|
February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
Haematologica
|
January 15, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
Naveen Pemmaraju, Marco Herling, Kendra L Sweet, et al.
American Journal of Hematology
|
February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Cancer
|
September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
The New England Journal of Medicine
|
April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-Response
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
The Lancet. Oncology
|
February 29, 2024
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Naval G Daver, Pau Montesinos, Daniel J DeAngelo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Leukemia Research
|
June 18, 2021
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy
Anthony M Hunter, Najla Al Ali, Anne Mai, et al.
Blood Advances
|
February 16, 2021
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Anthony M Hunter, Rami S Komrokji, Seongseok Yun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 12, 2022
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Kendra L Sweet, Anthony S Stein, et al.
Haematologica
|
January 15, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
Naveen Pemmaraju, Marco Herling, Kendra L Sweet, et al.
American Journal of Hematology
|
February 18, 2022
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Somedeb Ball, Akriti G Jain, Luis E Aguirre, et al.
Cancer
|
September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations
Somedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
The New England Journal of Medicine
|
April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-Response
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
The Lancet. Oncology
|
February 29, 2024
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Naval G Daver, Pau Montesinos, Daniel J DeAngelo, et al.
Page
of 3